Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Ascending Dose Study of E6742 in Japanese Healthy Adults
jRCT2031200316Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of e6742 in systemic lupus erythematosus (SLE) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Plasma concentration of E6742, Incidence of treatment-emergent adverse events (TEAEs) and 1 more. Started Dec 2020; status: completed.
02
Drugs
e6742
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2031200316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200316.